Strange. Nothing to strike off my list...just more questions. So far this can be interpreted as Prana transferring NEW PD movement disorder research from The Florey to Takeda. My turn at guessing is that the continued preclinical research will be done by Takeda International in the US where Dr. Stamler is located. To learn that it is centered on the gut is a surprise. Investors' reaction to the surprise is not much, as indicated by no change from $0.055 by PBT yesterday after GK's announcement and PRAN's loss of 15 cents to $2.64 and no after hours buying (a leak before the announcement?)
Why is there not any input from Takeda as would be expected in a collaboration announcement? It would be good to hear from Dr Stamler who is in charge of PBT434, Prana's new lead product with the best chance of entering clinical trials, to give some details of both sides of the "collaboration". A positive note is that it was repeated that Phase I should begin later this year.
PBT Price at posting:
5.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)